Sangamo Therapeutics (SGMO) Return on Sales (2016 - 2025)
Sangamo Therapeutics (SGMO) has disclosed Return on Sales for 16 consecutive years, with 2.63% as the latest value for Q4 2025.
- For Q4 2025, Return on Sales rose 97.0% year-over-year to 2.63%; the TTM value through Dec 2025 reached 3.11%, down 138.0%, while the annual FY2025 figure was 3.11%, 141.0% down from the prior year.
- Return on Sales hit 2.63% in Q4 2025 for Sangamo Therapeutics, up from 60.12% in the prior quarter.
- Across five years, Return on Sales topped out at 0.22% in Q3 2024 and bottomed at 102.06% in Q1 2024.
- Average Return on Sales over 5 years is 17.35%, with a median of 2.08% recorded in 2022.
- Year-over-year, Return on Sales crashed -10219bps in 2024 and then soared 10039bps in 2025.
- Sangamo Therapeutics' Return on Sales stood at 2.16% in 2021, then grew by 11bps to 1.91% in 2022, then plummeted by -1447bps to 29.53% in 2023, then surged by 88bps to 3.6% in 2024, then increased by 27bps to 2.63% in 2025.
- According to Business Quant data, Return on Sales over the past three periods came in at 2.63%, 60.12%, and 1.09% for Q4 2025, Q3 2025, and Q2 2025 respectively.